Profile
CHEPLAPHARM is a family-owned pharmaceutical company, headquartered in Germany. We offer our branded products on a global level.
By focusing on an internationally oriented Buy and Build Strategy, we generate annually increasing growth rates. The close collaboration with our business partners and our international subsidiaries allows CHEPLAPHARM to successfully realize its corporate strategy.
1998
Pharma manager Kurt Teubner establishes CHEPLAPHARM in Freiburg, Germany. The company’s name originates from one of the first products in our portfolio: CHEPLAREN®.
2003
The BRAUN family acquires the business with an annual turnover of 600k EURO. The firm’s headquarter is relocated to Mesekenhagen close to the Baltic Sea.
2003
Sebastian F. Braun succeeds as Chief Executive Officer (CEO) of CHEPLAPHARM.
Strategy realignment expressed by the phrase Specialty pharma meets M&A competence.
2004
The products Caye® and Talidat® are acquired from Medopharm and Merck Gruppe.
2006
Acquisition of ALDACTONE®, LANITOP® and ISOMONAT® in Austria from F. Hoffmann-La Roche Basel.
2006
In April, CHEPLAPHARM takes over Ky-Cor F Dragees, Ky-Cor Novo film-coated tablets and Ky- Thermopack from Merck-Gruppe.
2007
CHEPLAPHARM achieves an annual turnover of 3 million EURO, thus doubles the previous year’s result.
2007
Takeover of Aponal® in Germany from F. Hoffmann-La Roche Basel.
2008
In May, CHEPLAPHARM purchases Aquaphor® from Eli Lilly.
2008
In June, CHEPLAPHARM obtains the rights for Gelusil Lac® from the globally operating pharmaceutical manufacturer Johnson & Johnson.
2008
CHEPLAPHARM acquires the traditional Hamburg-based company Walter Ritter GmbH & Co. KG. Consequently, the product portfolio expands with the integration of ice sprays applied especially in the treatment of sports injuries.
2008
The generated sales of nearly 8 million EURO exceed all expectations. So far, this has been the most striking increase in turnover, thus the most successful fiscal year in CHEPLAPHARM’s history.
2009
CHEPLAPHARM continues its growth strategy. Six additional products are integrated into the portfolio: the PC 30® product line from Terra Bio Chemie GmbH, Baldrian Dispert®, one of the most famous German Baldrian brands, applied for sedation and in insomnia treatment, from Vemedia Manufacturing BV, the mineral supplements CalciAPS D3, Magnesium Tonil® Mono as well as Magnesium Tonil® plus Vitamin E from ProStrakan and the pharmaceutical product Apsomol® N from Dr. Willmar Schwabe GmbH & Co. KG, Karlsruhe, Germany.
2010
September - With the acquisition of DISTRANEURIN®/HEMINEVRIN® from the Swedish-British pharmaceutical company AstraZeneca, CHEPLAPHARM expands its presence in numerous European countries. The product generates revenues in the double-digit million range and is a crucial milestone for further internationalization projects of the company.
2011
In July, CHEPLAPHARM attains the rights for a range of products of long-established company Klosterfrau GmbH: Bactisubtil® complex, Enelbin® Paste, Eryfer® 100 and Eryfer® comp as well as Thüringer Kräutertinkturen. By means of this acquisition, CHEPLAPHARM further diversifies its portfolio.
2011
Through our successful merger and acquisition strategy, CHEPLAPHARM has achieved annual double-digit growth rates since 2003. Our export ratio accounts for more than 50 percent.
2012
100 percent takeover of company shares of the in Werne-based Sanavita Pharmaceuticals.
2012
In March, CHEPLAPHARM inaugurates its new logistics center in Neukenkirchen close to Greifswald.
2012
With the takeover of VESANOID® and ROHYPNOL® from F. Hoffmann-La Roche Basel in December, CHEPLAPHARM further maintains its internationalization strategy. Consequently, we further strengthen our position as provider of branded niche products and expand our territorial presence in more than 100 countries worldwide.
2013
Bianca Y. Juha, sister of CEO Sebastian F. Braun, assumes the position of Chief Scientific Officer (CSO).
2013
In September, CHEPLAPHARM acquires Reisegold®, applied in the treatment of travel sickness, as well as Halbmond® tablets for the short-term treatment of insomnia for the German market from Teva GmbH.
2013
Along with its subsidiaries, CHEPLAPHARM attains an annual turnover of 60 million EURO. Moreover, the number of employees increases to more than 70, thus CHEPLAPHARM contributes significantly to the regional development.
2014
The takeover of all company shares from New York-based Glenwood LLC and the purchase of the US-rights for the urology product POTABA® in January represents another Milestone for CHEPLAPHARM. This acquisition is a decisive step towards the further expansion and internationalization of our branded niche products.
2014
CHEPLAPHARM acquires the worldwide rights for POTABA®.
2014
With more than 25 years of experience in the pharmaceutical business, Edeltraud Lafer joins CHEPLAPHARM as Chief Operating Officer (COO) and perfectly complements the management team.
2014
Especially our European presence is notably reinforced by acquiring the UDCA products DEURSIL®/URSOLVAN® and a number of well-established OTC products from Sanofi.
2014
At the end of the year, CHEPLAPHARM opens the doors to its representative and modern office facilities located in the business park of the Hanseatic town of Greifswald. The well-being and the related intensification of teamwork of our currently 74 employees is thus ensured.
2015
At the beginning of the year, CHEPLAPHARM purchases the logistics center from RIEMSER Arzneimittel GmbH in Greifswald.
2015
In January, we expand our product portfolio in Italy by acquiring the product Streptosil® from Boehringer Ingelheim. Also, CHEPLAPHARM secures the German-wide rights for the antihypertensive agents Dopegyt® and Pertenso®, the painkiller Octadon® and the product Cotazym®, applied against digestive disorders, from UCB Pharma GmbH.
2015
In November, CHEPLAPHARM strengthens its presence on the Italian market by the successful acquisition of the prescription drug ALDACTONE® from Sanofi. Thereby, we repeatedly reinforce our international growth strategy.
2016
At the very beginning of the year, CHEPLAPHARM takes over the product rights for ANEXATE® from F. Hoffmann-La Roche Basel. The acquisition of the product ANEXATE® allows CHEPLAPHARM to create strategically important synergies with ROHYPNOL®. This product has already been acquired in 2012, consequently, ANEXATE® perfectly supplements CHEPLAPHARM’s product portfolio in the field of sedatives. The share of exports is thus increased to approximately 80 percent.
2016
End of September, contracts for the worldwide Rights of the Antiadipositum XENICAL® and the Betablocker DILATREND®have been signed. The contract for XENICAL® came into immediate force with day of signature on September 30th. The completion of the contract for DILATREND®, in short: the closing will take place beginning of January 2017. This transaction, worth of EURO 340 million the most significant one since CHEPLAPHARM was established and it is the largest privately owned investment in the Mecklenburg-Vorpommern region.
2016
CHEPLAPHARM concludes with an annual turnover of 121 million EURO, making it one of the largest medium-sized pharmaceutical companies within Germany. The number of employees increases to 120.
2017
The Closing for DILATREND® was completed in mid-January.
2017
Based on a marketing and distribution agreement with Orexigen Therapeutics Ltd., CHEPLAPHARM markets the product MYSIMBA® in Germany, France and Austria from August 2017. This prescription drug perfectly complements the anti-obesity drug XENICAL®, which was acquired in 2016.
2017
September - More than 150 employees from twelve different nations are currently working at CHEPLAPHARM. The company thus makes an important contribution to strengthening the economic power in the region and securing valuable jobs in Mecklenburg-Vorpommern.
2017
Per 01.12.2017, CHEPLAPHARM includes the OTC product range Calcivit D®/Calcivit D® Forte of the German generics company Hexal AG in its portfolio.
2017
With annual sales of 223 million euros, CHEPLAPHARM achieved another significant increase in sales in 2017.
2018
The Closing for the antiviral agent CYMEVENE® took place on 02.01.2018 with F. Hoffmann-La Roche Ltd.
2018
Per 03.01.2018, CHEPLAPHARM takes over the products KONAKION® MM, LARIAM® and INHIBACE®/Plus from F. Hoffmann-La Roche Ltd. Thus, CHEPLAPHARM continues its expansion course.
2018
CHEPLAPHARM further enhances its portfolio in the Cardiology area. Bristol-Myers Squibb’s product SOTALEX®/SOTACOR® has both beta-blocking and antiarrhythmic properties and is thus unique. In addition, the newly acquired product now further promotes the naturally existing synergies between CHEPLAPHARM's already successfully implemented Cardiology preparations.
2018
By acquiring the worldwide rights (except USA) for the product VISUDYNE® of the Swiss Novartis Pharma AG by 15.02.2018, CHEPLAPHARM is now active in the Ophthalmology Area.
2018
Since its foundation, CHEPLAPHARM has pursued a successful and sustainable growth strategy. As this development continues in 2018, the CHEPLAPHARM team already consists of 200 employees by June.
2018
CHEPLAPHARM secures the products rights for ATACAND® and ATACAND® Plus in 28 European markets from AstraZeneca. Contract signing took place in July, Closing is determined for end of September this year.
2018
Per August, CHEPLAPHARM takes over the global rights for QUESTRAN®. With this acquisition, the company intensifies the successful cooperation with Bristol-Myers Squibb.
2018
September - CHEPLAPHARM continues its successful expansion strategy by purchasing three more global niche products: FUNGIZONE®, VEPESID® and ETOPOPHOS®. This further strengthens the partnership and the professional cooperation with Bristol-Myers Squibb.
2018
From October, the company headquarters is officially relocated from Mesekenhagen to Greifswald. Constructed in 2014, CHEPLAPHARM’s representative and modern office facilities situated in the business park Ziegelhof are at present further extended with state-of-the-art office facilities. As a result, by the end of 2019, the company has enough space for its 250 employees (per December 2018).
2018
CHEPLAPHARM concludes the very successful fiscal year 2018 with the start of another large project: With the Closing in January 2019, the two products DORMICUM® and LEXOTAN® from F. Hoffmann-La Roche will be integrated into the already well-diversified CHEPLAPHARM portfolio.
2019
March - Just in time with the arrival of spring, CHEPLAPHARM celebrates the traditional topping-out ceremony at the company headquarters in the Hanseatic town of Greifswald (Ziegelhof). The rapidly growing company thus creates space for new offices on around 5,300 square meters. The new building is both a symbol of our company's success and a clear commitment to the company's business location.
2019
In May, CHEPLAPHARM received the “Axia Best Managed Companies Award” (Axia BMC Award) 2019, honouring best managed medium-sized companies in Germany.
2019
By the end of September, CHEPLAPHARM acquires the worldwide commercial rights - except China, Japan, the USA and Mexico - for the well-known branded product LOSEC®. With this investment we continue to strengthen our relationship with AstraZeneca and to pursue our internationally oriented business model.
2019
In the fourth quarter, AstraZeneca and CHEPLAPHARM agree to transfer the commercial rights for SEROQUEL® / SEROQUEL XR® and other related brands in Europe (excluding the United Kingdom) and North America. CHEPLAPHARM thereby expands its product portfolio with another established global branded product.
2020
At the beginning of the year CHEPLAPHARM places a High Yield Bond on the international bond market for the first time. This ensures the long-term financing in a sustainable and flexible manner.
2020
February - The extension at the company headquarters in Greifswald (Ziegelhof) has been completed. The functionally elegant new building of around 5,300 square meters offers CHEPLAPHARM’s more than 320 employees optimally equipped office- and work spaces.
2020
Being honoured with the highly coveted “Axia Best Managed Companies Award” in May, CHEPLAPHARM gets awarded as one of the best managed companies in Germany for the second time in a row.
2020
New acquisitions - With the purchase of a total of 25 different branded products in October 2019 and at the end of May 2020, we further enhance the diversification of our product portfolio.
2020
October - CHEPLAPHARM places 1 billion euros (equivalent) with institutional investors. With the help of this high-yield bond, several product portfolios in the therapeutic areas of cardiology, epilepsy, dermatology and hypertension were financed in the following months.
2020
In the fourth quarter of the year, CHEPLAPHARM demonstrates élan by concluding further attractive projects. These, among others, include 12 branded products that focus on the treatment of cardiological diseases and are mainly marketed in European countries.
CHEPLAPHARM also closes its first project with a new partner, the Danish pharmaceutical company LEO Pharma. The project includes four very well-established, off-patent branded products in the therapeutic areas dermatology, gynaecology and calcium metabolism.
CHEPLAPHARM has already held the rights for Atacand® and Atacand® Plus in 28 European markets since 2018. In 2020, the company also acquired the global rights (excluding the USA) for these two products from AstraZeneca.
At the end of the year, CHEPLAPHARM successfully concluded its largest acquisition to date with the Japanese company Takeda Pharmaceutical. This comprises a variety of branded products, aimed at the treatment of gastrointestinal diseases, sleep disorders and many others. The products will mainly be distributed in the European markets.
This is an impressive continuation of CHEPLAPHARM's success in previous years.
2021
CHEPLAPHARM starts the new year with the transfer of the commercial rights for Rivotril® from F. Hoffmann-La Roche.
2021
With effect from 1st March 2021, Edeltraud Lafer, COO (Chief Operating Officer) since 2014, hands her position to Patrick König, previously Director Global Sales. At the same time, Edeltraud Lafer as Co-CEO (Chief Executive Officer) and CEO Sebastian F. Braun will lead the company in the form of a dual leadership, clearly placing business development in the focus of the company's future.
2021
An expansion of the Executive Board comes into force from 1st April 2021. As an additional member, Dr Keyarasch "Kia" Parssanedjad, M.D., joins the company's Executive Board as Chief Corporate Investment Officer (CIO).
